Santen to Present Latest Data including STN1012700 (DE-127) and STN1007603 (DE-076C) at 33rd APACRS 2021 meeting

1 July 2 9, 2021 Santen to Present Latest Data including STN1012700 (DE-127) and STN1007603 (DE-076C) at 33rd APACRS 2021 meeting Santen Pharmaceutical Co., Ltd. ( Head Office in Osaka, hereinafter “Santen”) announced today that some publications related to STN1012700 (DE-127), a non -selective muscarinic antagonist, STN1007603 (DE-076C), an ophthalmic emulsion which has immunosuppressive effect, etc. will be presented at the virtual Asia-Pacific Association of Cataract and Refractive Surge ons (33rd APACRS; http://apacrs-snec2021.org/) meeting from July 30 to 31, 2021. STN1007603 has been launched as Verkazia for the treatment of vernal keratoconjunctivitis in several countries including Europe and Asia. Verkazia was also recently approved in U.S. in June 2021 and a marketing approval has been submitted in China in April 2021. Santen has also been conducting a Phase 2/3 study to investigate STN1012700 (DE-127) for slowing myopia progression in children in Japan and plans to initiate a Phase 1 study in China in FY2021. The recent Phase 2 study data of STN10127 from APPLE study in Asia and pooled safety data of Verkazia from NOVATIVE/VEKTIS Phase 3 stud ies, that were included in the U.S. label will be presented at APACRS meeting this year. Presentation topics Poster ID Title PP5-66 Efficacy and Safety of DE-127 versus Placebo in Mild or Moderate Myopia: The APPLE study PP5-67 Changes in Axial Length of DE-127 (0.0025%, 0.005%, 0.01%) versus Placebo for Slowing Myopia Progression: The APPLE study PP5-15 Safety/Tolerability of Topical Cyclosporine A Cationic Emulsion in Pediatric Patients with Active Severe VKC: Pooled NOVATIVE/VEKTIS trial results PP5-97 Safety Outcomes of Microshunt Implantation vs. Trabeculectomy in Patients with Primary Open-angle Glaucoma In addition, Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling products in the Americas, Australia, and New Zealand (press release on May 19, 2021; https://www.santen.com/en/news/20210519-1.pdf). 2 Contact: Investor Relations Group Santen Pharmaceutical Co., Ltd. E-mail: [email protected]

The release as fetched from its publisher. santen.com ↗